Lilly’s revenue soars 48%, driven by demand for its GLP-1s
corporate_earningsUnited StatesMarketWatch5 Aug, 20:45 UTC
Context
Lilly’s revenue soars 48%, driven by demand for its GLP-1s MarketWatch Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge CNBC Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo Reuters Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress Eli Lilly and Company Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand WSJ
What it means
Causal chain
No clear market signal
How to read a signal
- Severity
- the event's market impact, 1–5
- Direction
- ↑ / ↓ likely price move for the asset
- Exp. move
- the size of the abnormal move we'd expect if the call plays out — not a claim a move will happen:Most flagged events don't move beyond noise; those count against us (see the track record).Ssmall<1%Mmoderate1–5%Llarge>5%
- Timeframe
- the window we measure over:1dshort5dmedium21dlong
- Conviction
- how well-established the directional call is (textbook → speculative) — not a guaranteed outcome:lowaveragestrong
Get the next signal the moment it breaks.
The full live feed, asset filters, and alerts — free.
Sign up free →Not investment advice · for informational purposes only. Generated 6 Aug, 01:32 UTC